Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge

Virology

Volumn 395, Issue 2, 2009, Pages 182-189

  Park, Ki Seok ^a   Lee, Jiyeung ^b   Ahn, So Shin ^a   Byun, Young Ho ^c   Seong, Baik Lin ^c   Baek, Yun Hee ^d   Song, Min Suk ^d   Choi, Young Ki ^a   Na, Yun Jeong ^a   Hwang, Inhwan ^a   Sung, Young Chul ^a,b   Lee, Chang Geun ^b  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b POSTECH Biotech Center   (South Korea)

^c Yonsei University   (South Korea)

^d Chungbuk National University College of Medicine   (South Korea)

Author keywords

Adenovirus; Influenza; Mucosal immunity; Prime boost; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; AVIAN INFLUENZA VACCINE; CD40 LIGAND; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PROTEIN M1; PROTEIN M2; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; AVIAN INFLUENZA; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; INFLUENZA VIRUS A H5N1; INTERNAL RIBOSOME ENTRY SITE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; VIRUS RECOMBINANT;

ADMINISTRATION, INTRANASAL; ANIMALS; BODY WEIGHT; CD8-POSITIVE T-LYMPHOCYTES; IMMUNITY, MUCOSAL; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H5N2 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION;

ADENOVIRIDAE; AVES; AVIAN INFLUENZA VIRUS;

EID: 70450221678     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.09.018     Document Type: Article

References (44)

1. Appaiahgari M.B., Saini M., Rauthan M., Jyoti, and Vrati S. Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect. 8 1 (2006) 92-104
2. Baig J., Levy D.B., McKay P.F., Schmitz J.E., Santra S., Subbramanian R.A., Kuroda M.J., Lifton M.A., Gorgone D.A., Wyatt L.S., Moss B., Huang Y., Chakrabarti B.K., Xu L., Kong W.P., Yang Z.Y., Mascola J.R., Nabel G.J., Carville A., Lackner A.A., Veazey R.S., and Letvin N.L. Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J. Virol. 76 22 (2002) 11484-11490
3. Bangari D.S., and Mittal S.K. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24 7 (2006) 849-862
4. Bednarek M.A., Engl S.A., Gammon M.C., Lindquist J.A., Porter G., Williamson A.R., and Zweerink H.J. Soluble HLA-A2.1 restricted peptides that are recognized by influenza virus specific cytotoxic T lymphocytes. J. Immunol. Methods 139 1 (1991) 41-47
5. Bublot M., Le Gros F.X., Nieddu D., Pritchard N., Mickle T.R., and Swayne D.E. Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand. Avian Dis. 51 1 Suppl. (2007) 332-337
6. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., Gu L., Martin J.E., Novik L., Chakrabarti B.K., Butman B.T., Gall J.G., King C.R., Andrews C.A., Sheets R., Gomez P.L., Mascola J.R., Nabel G.J., and Graham B.S. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 194 12 (2006) 1638-1649
7. Cate T.R., Couch R.B., Parker D., and Baxter B. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines-1978. Rev. Infect. Dis. 5 4 (1983) 737-747
8. Clements M.L., and Murphy B.R. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J. Clin. Microbiol. 23 1 (1986) 66-72
9. Epstein S.L., Kong W.P., Misplon J.A., Lo C.Y., Tumpey T.M., Xu L., and Nabel G.J. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23 46-47 (2005) 5404-5410
10. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., Fu T.M., Joyce J., Przysiecki C.T., Keller P.M., Garsky V.M., Ionescu R., Rippeon Y., Shi L., Chastain M.A., Condra J.H., Davies M.E., Liao J., Emini E.A., and Shiver J.W. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22 23-24 (2004) 2993-3003
11. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., Robbins P.D., Swayne D.E., Donis R.O., Katz J.M., Barratt-Boyes S.M., and Gambotto A. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol. 80 4 (2006) 1959-1964
12. Gianfrani C., Oseroff C., Sidney J., Chesnut R.W., and Sette A. Human memory CTL response specific for influenza A virus is broad and multispecific. Hum. Immunol. 61 5 (2000) 438-452
13. Hien T.T., de Jong M., and Farrar J. Avian influenza-a challenge to global health care structures. N. Engl. J. Med. 351 23 (2004) 2363-2365
14. Hoelscher M.A., Garg S., Bangari D.S., Belser J.A., Lu X., Stephenson I., Bright R.A., Katz J.M., Mittal S.K., and Sambhara S. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367 9509 (2006) 475-481
15. Hoelscher M.A., Jayashankar L., Garg S., Veguilla V., Lu X., Singh N., Katz J.M., Mittal S.K., and Sambhara S. New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin. Pharmacol. Ther. 82 6 (2007) 665-671
16. Holman D.H., Wang D., Raja N.U., Luo M., Moore K.M., Woraratanadharm J., Mytle N., and Dong J.Y. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. Vaccine 26 21 (2008) 2627-2639
17. Horimoto T., and Kawaoka Y. Strategies for developing vaccines against H5N1 influenza A viruses. Trends. Mol. Med. 12 11 (2006) 506-514
18. Ito T., Gorman O.T., Kawaoka Y., Bean W.J., and Webster R.G. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J. Virol. 65 10 (1991) 5491-5498
19. Jameson J., Cruz J., and Ennis F.A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J. Virol. 72 11 (1998) 8682-8689
20. Kilian M., and Russell M.W. Microbial evasion of IgA functions. In: Ogra P e.a. (Ed). Mucosal immunology (1999), Academic Press, San Diego 241-251
21. Kistner O., Howard M.K., Spruth M., Wodal W., Bruhl P., Gerencer M., Crowe B.A., Savidis-Dacho H., Livey I., Reiter M., Mayerhofer I., Tauer C., Grillberger L., Mundt W., Falkner F.G., and Barrett P.N. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25 32 (2007) 6028-6036
22. Lee C.G., Choi S.Y., Park S.H., Park K.S., Ryu S.H., and Sung Y.C. The synthetic peptide Trp-Lys-Tyr-Met-Val-d-Met as a novel adjuvant for DNA vaccine. Vaccine 23 38 (2005) 4703-4710
23. Lee J.H., Pascua P.N.Q., Song M.S., Baek Y.H., Kim C.J., Choi H.W., Sung M.H., Webby R.J., Webster R.G., Poo H., and Choi Y.K. Isolation and genetic characterization of H5N2 influenza viruses from pigs in Korea. J. Virol. 83 9 (2009) 4205-4215
24. Lefrançois L. Cytotoxic T cells of the mucosal immune system. 3rd ed. In: Mestecky J., Bienenstock J., Lamm M.E., Mayer L., Strober W., and McGhee J.R. (Eds). Mucosal immunology (2005), Academic Press/Elsevier, San Diego p559-564
25. Lemiale F., Kong W.P., Akyurek L.M., Ling X., Huang Y., Chakrabarti B.K., Eckhaus M., and Nabel G.J. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol. 77 18 (2003) 10078-10087
26. Li W. Synergistic antibody induction by antigen-CD40 ligand fusion protein as improved immunogen. Immunology 115 2 (2005) 215-222
27. Li K.S., Guan Y., Wang J., Smith G.J., Xu K.M., Duan L., Rahardjo A.P., Puthavathana P., Buranathai C., Nguyen T.D., Estoepangestie A.T., Chaisingh A., Auewarakul P., Long H.T., Hanh N.T., Webby R.J., Poon L.L., Chen H., Shortridge K.F., Yuen K.Y., Webster R.G., and Peiris J.S. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 430 6996 (2004) 209-213
28. Liu W., Peng Z., Liu Z., Lu Y., Ding J., and Chen Y.H. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 23 3 (2004) 366-371
29. Martinez-Salas E. Internal ribosome entry site biology and its use in expression vectors. Curr. Opin. Biotechnol. 10 5 (1999) 458-464
30. McMichael A.J., Gotch F.M., Noble G.R., and Beare P.A. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309 1 (1983) 13-17
31. Ninomiya A., Imai M., Tashiro M., and Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25 18 (2007) 3554-3560
32. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., Santiago S., Marmor M., Lally M., Novak R.M., Brown S.J., Kulkarni P., Dubey S.A., Kierstead L.S., Casimiro D.R., Mogg R., DiNubile M.J., Shiver J.W., Leavitt R.Y., Robertson M.N., Mehrotra D.V., and Quirk E. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46 11 (2008) 1769-1781
33. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., Perdue M., Swayne D., Bender C., Huang J., Hemphill M., Rowe T., Shaw M., Xu X., Fukuda K., and Cox N. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279 5349 (1998) 393-396
34. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., Hogan R.J., Wu Z., Benton K.A., Tumpey T.M., and Epstein S.L. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 13 3 (2007) 426-435
35. Toro H., Tang D.C., Suarez D.L., Sylte M.J., Pfeiffer J., and Van Kampen K.R. Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector. Vaccine 25 15 (2007) 2886-2891
36. Toro H., Tang D.C., Suarez D.L., Zhang J., and Shi Z. Protection of chickens against avian influenza with non-replicating adenovirus-vectored vaccine. Vaccine 26 21 (2008) 2640-2646
37. Treanor J.J., Schiff G.M., Couch R.B., Cate T.R., Brady R.C., Hay C.M., Wolff M., She D., and Cox M.M. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J. Infect. Dis. 193 9 (2006) 1223-1228
38. Ungchusak K., Auewarakul P., Dowell S.F., Kitphati R., Auwanit W., Puthavathana P., Uiprasertkul M., Boonnak K., Pittayawonganon C., Cox N.J., Zaki S.R., Thawatsupha P., Chittaganpitch M., Khontong R., Simmerman J.M., and Chunsutthiwat S. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 352 4 (2005) 333-340
39. Van Kampen K.R., Shi Z., Gao P., Zhang J., Foster K.W., Chen D.T., Marks D., Elmets C.A., and Tang D.C. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23 8 (2005) 1029-1036
40. Wang J., Thorson L., Stokes R.W., Santosuosso M., Huygen K., Zganiacz A., Hitt M., and Xing Z. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173 10 (2004) 6357-6365
41. WHO. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO (2009)
42. Xiang Z.Q., Gao G.P., Reyes-Sandoval A., Li Y., Wilson J.M., and Ertl H.C. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J. Virol. 77 20 (2003) 10780-10789
43. Zhang L., Tang Y., Akbulut H., Zelterman D., Linton P.J., and Deisseroth A.B. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 100 25 (2003) 15101-15106
44. Zharikova D., Mozdzanowska K., Feng J., Zhang M., and Gerhard W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J. Virol. 79 11 (2005) 6644-6654